Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLS006 in Cutaneous Common Warts
NCT03259620Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Oct 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in common warts comparing CLS006 with Vehicle (2 arms). Primary endpoint: Proportion of Subjects With Complete Clearance of All Treated Warts at 18 weeks. Started Oct 2017; status: completed.
02
Drugs
furosemide
03
Conditions
common warts
Beyond the preview
Go deeper on NCT03259620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259620.